22 30

Cited 0 times in

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer

 Yong Jae Lee  ;  Hyun-Soo Kim  ;  John Hoon Rim  ;  Jung-Yun Lee  ;  Eun Ji Nam  ;  Sang Wun Kim  ;  Sunghoon Kim  ;  Young Tae Kim 
 BMC CANCER, Vol.20(1) : 185, 2020-03 
Journal Title
Issue Date
Adult ; Aged ; BRCA1 Protein / genetics* ; BRCA2 Protein / genetics* ; Cystadenocarcinoma, Serous / genetics ; Cystadenocarcinoma, Serous / pathology ; Cystadenocarcinoma, Serous / therapy* ; Cytoreduction Surgical Procedures ; Drug Therapy / methods* ; Female ; Germ-Line Mutation* ; Gynecologic Surgical Procedures / methods* ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Ovarian Neoplasms / genetics ; Ovarian Neoplasms / pathology ; Ovarian Neoplasms / therapy* ; Retrospective Studies ; Survival Analysis ; Treatment Outcome
Chemotherapy response scores ; Germline BRCA ; Neoadjuvant chemotherapy ; Ovarian cancer
Background: To analyze the effects of BRCA1/2 mutations on chemotherapy response scores (CRS) and survival in a cohort of patients with advanced-stage ovarian cancer who were treated with neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS). Methods: We retrospectively reviewed the medical records of 169 high-grade serous ovarian cancer patients who underwent a germline BRCA1/2 test and received three cycles of NAC at the Yonsei Cancer Center from 2006 to 2018. Chemotherapy response scores were compared in patients with and without BRCA1/2 mutations. The effects of BRCA1/2 mutations and CRS on survival were evaluated. Results: BRCA1/2 mutations were detected in 47 (28.1%) of the 169 patients. Overall, 16 (34.0%) patients with BRCA1/2 mutations had a CRS 3 to chemotherapy compared to scores of 43 in patients (35.2%) without a mutation. Response scores of 3 in patients with BRCA1/2 mutations were not significantly associated with either improved progression-free survival (PFS) (P = 0.949) or overall survival (OS) (P = 0.168). However, CRS 3 in patients without BRCA mutations was significantly associated with both improved PFS (P = 0.030) and OS (P = 0.039). In patients with CRS1/2, carriers of BRCA1/2 mutations had better PFS (P = 0.0344) and OS (P = 0.043) than wild-type BRCA genotype patients. Conclusion: In ovarian cancer patients treated with NAC, CRS did not predict survival for BRCA 1/2 mutation carriers but did for BRCA wild-type patients.
Files in This Item:
T202004889.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Kim, Sang Wun(김상운) ORCID logo https://orcid.org/0000-0002-8342-8701
Kim, Sung Hoon(김성훈) ORCID logo https://orcid.org/0000-0002-1645-7473
Kim, Young Tae(김영태) ORCID logo https://orcid.org/0000-0002-7347-1052
Kim, Hyun-Soo(김현수)
Nam, Eun Ji(남은지) ORCID logo https://orcid.org/0000-0003-0189-3560
Lee, Yong Jae(이용재) ORCID logo https://orcid.org/0000-0003-0297-3116
Lee, Jung-Yun(이정윤) ORCID logo https://orcid.org/0000-0001-7948-1350
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.